Form 8-K - Current report:
SEC Accession No. 0001104659-23-029022
Filing Date
2023-03-06
Accepted
2023-03-06 16:21:07
Documents
13
Period of Report
2023-03-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm238572d1_8k.htm   iXBRL 8-K 27393
2 EXHIBIT 99.1 tm238572d1_ex99-1.htm EX-99.1 12220
  Complete submission text file 0001104659-23-029022.txt   219511

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20230302.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20230302_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20230302_pre.xml EX-101.PRE 22599
7 EXTRACTED XBRL INSTANCE DOCUMENT tm238572d1_8k_htm.xml XML 3606
Mailing Address 3415 COLORADO AVE. BOULDER CO 80303
Business Address 3415 COLORADO AVE. BOULDER CO 80303 303-735-8373
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 23709207
SIC: 2834 Pharmaceutical Preparations